Lianghui Cheng

Dr. Lianghui Cheng


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
LCLianghui Cheng
Lianghui Cheng
ZZZhiyong Zhuang
Zhiyong Zhuang
MYMingming Yin
Mingming Yin
YLYuan Lu
Yuan Lu
SLSujuan Liu
Sujuan Liu
Liang LuoLiang Luo
Liang Luo
Diabetic wounds are usually entangled in a disorganized and self-perpetuating microenvironment and accompanied by a prolonged delay in tissue repair. Sustained and coordinated microenvironment regulation and tissue regeneration are key to the healing process of diabetic wounds, yet they continue to pose a formidable challenge. Here we report a rational double-layered dressing design based on chitosan and a degradable conjugated polymer polydiacetylene, poly(deca-4,6-diynedioic acid) (PDDA), that can meet this intricate requirement. With an alternating ene-yne backbone, PDDA degrades when reacting with various types of reactive oxygen species (ROS), and more importantly, generates proliferative succinic acid as a major degradant. Inheriting from PDDA, the developed PDDA-chitosan double layer dressing (PCD) can eliminate ROS in the microenvironment of diabetic wounds, alleviate inflammation, and downregulate gene expression of innate immune receptors. PCD degradation also triggers simultaneous release of succinic acid in a sustainable manner, enabling long-term promotion on tissue regeneration. We have validated the biocompatibility and excellent performance of PCD in expediting the wound healing on both diabetic mouse and porcine models, which underscores the significant translational potential of this microenvironment-modulating, growth-promoting wound dressing in diabetic wounds care.

12 April 2020 in Critical Reviews in Food Science and Nutrition
Verified
Journal Article
Open access
LCLianghui Cheng
Lianghui Cheng
RARenate Akkerman
Renate Akkerman
CKChunli Kong
Chunli Kong
MWMarthe T. C. Walvoort
Marthe T. C. Walvoort
Paul De VosPaul De Vos
Paul De Vos
Human milk is the gold standard for newborn infants. Breast milk not only provides nutrients, it also contains bioactive components that guide the development of the infant’s intestinal immune system, which can have a lifelong effect. The bioactive molecules in breast milk regulate microbiota development, immune maturation and gut barrier function. Human milk oligosaccharides (hMOs) are the most abundant bioactive molecules in human milk and have multiple beneficial functions such as support of growth of beneficial bacteria, anti-pathogenic effects, immune modulating effects, and stimulation of intestine barrier functions. Here we critically review the current insight into the benefits of bioactive molecules in mother milk that contribute to neonatal development and focus on current knowledge of hMO-functions on microbiota and the gastrointestinal immune barrier. hMOs produced via genetically engineered microorganisms are now applied in infant formulas to mimic the nutritional composition of breast milk as closely as possible, and their prospects and scientific challenges are discussed in depth.

29 May 2019 in Molecular Nutrition & Food Research
Verified
Journal Article
Open access
PDF file
CKChunli Kong
Chunli Kong
MEMarlies Elderman
Marlies Elderman
LCLianghui Cheng
Lianghui Cheng
BHBart J. de Haan
Bart J. de Haan
ANArjen Nauta
Arjen Nauta
Paul De VosPaul De Vos
Paul De Vos
Scope: The epithelial glycocalyx development is of great importance for microbial colonization. Human milk oligosaccharides (hMOs) and non‐digestible carbohydrates (NDCs) may modulate glycocalyx development.Methods and results: The effects of hMOs and NDCs on human gut epithelial cells (Caco2) are investigated by quantifying thickness and area coverage of adsorbed albumin, heparan sulfate (HS), and hyaluronic acid (HA) in the glycocalyx. Effects of hMOs (2′‐FL and 3‐FL) and NDCs [inulins with degrees of polymerization (DP) (DP3‐DP10, DP10‐DP60, DP30‐DP60) and pectins with degrees of methylation (DM) (DM7, DM55, DM69)] are tested using immunofluorescence staining at 1 and 5 days stimulation. HMOs show a significant enhancing effect on glycocalyx development but effects are structure‐dependent. 3‐FL induces a stronger albumin adsorption and increases HS and HA stronger than 2′‐FL. The DP3‐DP10, DP30‐60 inulins also increase glycocalyx development in a structure‐dependent manner as DP3‐DP10 selectively increases HS, while DP30‐DP60 specifically increases HA. Pectins have less effects, and only increase albumin adsorption.Conclusion: Here, it is shown that 2′‐FL and 3‐FL and inulins stimulate glycocalyx development in a structure‐dependent fashion. This may contribute to formulation of effective hMO and NDC formulations in infant formulas to support microbial colonization and gut barrier function.

4 December 2019 in Molecular Nutrition & Food Research
Verified
Journal Article
Open access
PDF file
LCLianghui Cheng
Lianghui Cheng
CKChunli Kong
Chunli Kong
MWMarthe T. C. Walvoort
Marthe T. C. Walvoort
MFMarijke M. Faas
Marijke M. Faas
Paul De VosPaul De Vos
Paul De Vos
Scope: Human milk oligosaccharides (hMOs) have beneficial effects on intestinal barrier function, but the mechanisms of action are not well understood. Here, the effects of hMOs on goblet cells, which indicate that some hMOs may enhance mucus barrier function through direct modulation of goblet cell function, are studied.Methods and results: The modulatory effects of 2′‐fucosyllactose (2′‐FL), 3‐fucosyllactose (3‐FL), lacto‐N‐triaose II (LNT2), and galacto‐oligosaccharides (GOS) on the expression of goblet cell secretory related genes MUC2, TFF3, and RETNLB, and the Golgi‐sulfotransferase genes CHST5 and GAL3ST2 of LS174T are determined by real‐time quantitative RT‐PCR. 3‐FL, LNT2, and GOS‐modulated LS174T gene expression profiles in a dose‐ and time‐dependent manner. In addition, the upregulation of MUC2 is confirmed by immunofluorescence staining. Effects of 2′‐FL, 3‐FL, LNT2, and GOS on gene transcription of LS174T are also assessed during exposure to TNF‐α, IL‐13, or tunicamycin. During TNF‐α challenge, 3‐FL and LNT2 enhance MUC2 and TFF3 gene expression. After IL‐13 exposure, 2′‐FL, 3‐FL, and LNT2 all show upregulating effects on MUC2; 3‐FL and LNT2 also enhance TFF3 expression. LNT2 significantly reverses Tm‐induced downregulation of TFF3, RETNLB, and CHST5.Conclusion: The findings indicate that hMOs may enhance mucus barrier function through direct modulation of intestinal goblet cells. Effects are structure‐ and stressor‐dependent.

1 August 2019 in Journal of Functional Foods
Verified
Journal Article
Open access
LCLianghui Cheng
Lianghui Cheng
MKMensiena B.G. Kiewiet
Mensiena B.G. Kiewiet
AGAndre Groeneveld
Andre Groeneveld
ANArjen Nauta
Arjen Nauta
Paul De VosPaul De Vos
Paul De Vos

19 January 2021 in Molecular Nutrition & Food Research
Verified
Journal Article
Open access
PDF file
LCLianghui Cheng
Lianghui Cheng
CKChunli Kong
Chunli Kong
WWWenjia Wang
Wenjia Wang
AGAndre Groeneveld
Andre Groeneveld
ANArjen Nauta
Arjen Nauta
Paul De VosPaul De Vos
Paul De Vos
Scope Human milk oligosaccharides (hMOs) can attenuate inflammation by modulating intestinal epithelial cells, but the mechanisms of action are not well‐understood. Here we study the effects of hMOs on TNF‐α induced inflammatory events in gut epithelial cells. Methods and results The modulatory effects of 2’‐FL, 3‐FL, 6’‐SL, LNT, LNnT, LDFT, and LNT2 on immature FHs 74 Int intestinal epithelial cells and on adult T84 intestinal epithelial cells with or without TNF‐α exposure were determined. IL‐8 secretion in FHs 74 Int and T84 were quantified to determine possible hMO induced attenuation of inflammatory events by ELISA. 3‐FL, LNnT, and LDFT significantly attenuated TNF‐α induced inflammation in FHs 74 Int, while LNT2 induced IL‐8 secretion in T84. In addition, microscale thermophoresis assays and ELISA were used to study the possible mechanisms of interaction between effective hMOs and TNFR1. 3‐FL, LNnT, and LDFT exerted TNFR1 ectodomain shedding while LNnT also showed binding affinity to TNFR1 with a Kd of 900 ± 660 nM as measured with microscale thermophoresis. Conclusion Our findings indicate that specific hMO types attenuate TNF‐α induced inflammation in fetal gut epithelial cells through TNFR1 in a hMO structure‐dependent fashion suggest possibilities to apply hMOs in management of TNF‐α dependent diseases. This article is protected by copyright. All rights reserved